This test uses targeted next-generation sequencing to evaluate for somatic mutations within the EGFR, BRAF, KRAS, HRAS, NRAS, ALK, ERBB2, and MET genes. Next-generation sequencing is also used to identify rearrangements (fusions) involving ALK, ROS1, RET, and NTRK1.
When this test is ordered, slide review will always be performed at an additional charge.
Third Generation LH assay
Ultrasensitive LH assay
Lyme CNS Infection IgG Screen
Reflex test: Lyme CNS Infection, IgG
Blastogenesis Antigens Immune Competence Lymphocyte Blastogenesis Antigen Lymphocyte Phytohemagglutiin Lymphocyte Transformation
If insufficient peripheral blood mononuclear cells (PBMCs) are isolated from the patient's sample due to low WBC counts or specimen volume received, selected dilutions or stimulants may not be tested at the discretion of the laboratory to ensure the most reliable results. Testing with 1 stimulant will always be performed. When adequate specimen is available for both stimulants to be tested, an additional test ID will be reflexed and billed separately.
Alpha-Fucosidosis, Alpha-Galactosidase Deficiency, Alpha-Mannosidosis, Alpha-N-Acetylgalactosaminidase Deficiency, Arylsulfatase A Deficiency, Arylsulfatase B Deficiency, Aspartylglucosaminuria, Aspartylglycosaminuria, Beta-Galactosidase Deficiency, Beta-Glucuronidase Deficiency, Ceramide Hexosides, Ceramide Trihexosidase, Ceramide Trihexosidase Deficiency, Chondroitin-6-sulfate, Chondroitin-6 sulfate, Dermatan Sulfate, Diffuse Angiokeratoma, Fabry Disease, Fabry's Disease, GAGS (Glycosaminoglycans), Galactose-6-Sulfatase Deficiency, Galactosialidosis, GB3, GL3, Globotriaosylceramide, Glycosaminoglycans (GAGS), GM1 gangliosidosis, GM2 gangliosidosis, Heparan Sulfate, Hunter Syndrome, Hurler Syndrome, Hurler-Scheie Syndrome, I-Cell Disease, Iduronate Sulfatase Deficiency, Iduronidase Deficiency, Keratan Sulfate, LSD, Lysosomal Storage, Lysosomal Storage Disease, Maroteaux Lamy Syndrome, Maroteaux-Lamy Syndrome, Metachromatic Leukodystrophy, Morquio A, Morquio B, MPS I, MPS II, MPS III, MPS IVA, MPS IVB, MPS VI, MPS VII, Mucolipidosis II, Mucolipidosis III, Mucopolysaccharides, Mucopolysaccharidosis, Multiple Sulfatase Deficiency, Oligosaccharides, Oligosaccharidosis, Pompe Disease, Pseudo-Hurler Polydystrophy, Sandhoff Disease, Sanfilippo Syndrome, Scheie Syndrome, Schindler Disease, Sialidosis, Sly Syndrome, Sphingolipids, Sulfatides
This is a general urine screening test for a broad array of lysosomal storage (LSD) and related disorders. Not all LSDs are detectable by this method.
The first step in a diagnostic workup of an individual suspected of having a lysosomal storage disorder (LSD) includes urine analyses for metabolites associated with mucopolysaccharidoses, oligosaccharidoses, disorders of sulfatide degradation, and LSDs with characteristic urine profiles.
This test contains a combined analysis of ceramide trihexosides, mucopolysaccharides, oligosaccharides, and sulfatides. This combined analysis of these disease-specific markers allows for the identification of disorders that may not be picked up using any of the single tests alone.